Free Trial

Serina Therapeutics (SER) 10K Form and Latest SEC Filings 2026

Serina Therapeutics logo
$1.80 -0.10 (-5.26%)
Closing price 04:10 PM Eastern
Extended Trading
$1.82 +0.02 (+0.89%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Serina Therapeutics SEC Filings & Recent Activity

Serina Therapeutics (NYSEAMERICAN:SER) has submitted 313+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G submitted on May 4, 2026.

Form 4
Serina Therapeutics, Inc. Reports Ownership Change on Apr. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Serina Therapeutics Files Current Report on Apr. 21, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Serina Therapeutics Files Annual Report on Mar. 27, 2026

The 10-K contains Serina Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Serina Therapeutics SEC Filing History

Browse Serina Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 3:15 PM
Serina Therapeutics (1708599) Subject
Sio Capital Management, LLC (1482416) Filed by
Form SCHEDULE 13G
04/28/2026 3:17 PM
Serina Therapeutics (1708599) Filer
Form DEFA14A
04/21/2026 4:12 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/21/2026 2:45 PM
Bailey Gregory (1329505) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 2:31 PM
Serina Therapeutics (1708599) Issuer
Venkatesan Jay (1413350) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 4:12 PM
Serina Therapeutics (1708599) Filer
Form PRE 14A
03/27/2026 12:57 PM
Serina Therapeutics (1708599) Filer
Form 10-K/A
03/25/2026 4:31 PM
Serina Therapeutics (1708599) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/25/2026 3:08 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2026 6:24 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:07 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2026 1:20 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:24 AM
GILL SIMBA (1180763) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:29 AM
Serina Therapeutics (1708599) Issuer
Tenjarla Srini (2029985) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:35 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:20 AM
LEDGER STEVEN A (1090206) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2026 11:15 PM
Serina Therapeutics (1708599) Filer
Form EFFECT
02/03/2026 11:35 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 4:19 PM
Serina Therapeutics (1708599) Filer
Form S-3
Registration statement under Securities Act of 1933  
01/29/2026 11:54 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 11:35 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 6:17 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2026 3:03 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/14/2026 11:56 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 11:27 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 10:40 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 1:04 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 6:56 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:59 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 11:48 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2025 3:17 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/04/2025 6:56 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 4:21 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 8:20 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 12:47 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 5:03 AM
Serina Therapeutics (1708599) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2025 5:05 AM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 11:36 AM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 11:38 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 6:57 PM
Serina Therapeutics (1708599) Issuer
Venkatesan Jay (1413350) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 7:02 PM
Marshall Richard Peter (2016188) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 7:05 PM
Bailey Gregory (1329505) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 7:09 PM
Brannan Stephen K. (1777631) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 6:30 PM
Serina Therapeutics (1708599) Issuer
WILSON KAREN J (1267490) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2025 3:40 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2025 2:29 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2025 5:03 AM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/29/2025 4:04 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2025 12:22 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 3:02 PM
Serina Therapeutics (1708599) Filer
Form DEFR14A
10/21/2025 11:24 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/14/2025 3:48 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 12:16 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2025 3:12 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2025 11:19 AM
Serina Therapeutics (1708599) Filer
Form DEFA14A
09/26/2025 10:29 AM
Serina Therapeutics (1708599) Filer
Form DEF 14A
09/15/2025 4:06 PM
Serina Therapeutics (1708599) Filer
Form PRE 14A
09/15/2025 3:01 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 2:23 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 4:16 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:13 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 4:22 PM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 5:03 AM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2025 5:10 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2025 9:40 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2025 9:47 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025 10:00 AM
Moreadith Randall (1301120) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:36 PM
Brannan Stephen K. (1777631) Reporting
Serina Therapeutics (1708599) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:20 PM
Brannan Stephen K. (1777631) Reporting
Serina Therapeutics (1708599) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/22/2025 3:40 PM
Serina Therapeutics (1708599) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Serina Therapeutics SEC Filings - Frequently Asked Questions

Serina Therapeutics (SER) has submitted 313+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Serina Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SCHEDULE 13G submitted on May 4, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSEAMERICAN:SER) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners